These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 28808917)

  • 21. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
    Bender BC; Schaedeli-Stark F; Koch R; Joshi A; Chu YW; Rugo H; Krop IE; Girish S; Friberg LE; Gupta M
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):591-601. PubMed ID: 22886072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
    Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
    Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
    Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
    Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs).
    Scheuher B; Ghusinga KR; McGirr K; Nowak M; Panday S; Apgar J; Subramanian K; Betts A
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):429-447. PubMed ID: 37787918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
    Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
    AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
    Poon KA; Flagella K; Beyer J; Tibbitts J; Kaur S; Saad O; Yi JH; Girish S; Dybdal N; Reynolds T
    Toxicol Appl Pharmacol; 2013 Dec; 273(2):298-313. PubMed ID: 24035823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S; Li Z; Bussing D; Shah DK
    Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADME of antibody-maytansinoid conjugates.
    Erickson HK; Lambert JM
    AAPS J; 2012 Dec; 14(4):799-805. PubMed ID: 22875610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
    Dere R; Yi JH; Lei C; Saad OM; Huang C; Li Y; Baudys J; Kaur S
    Bioanalysis; 2013 May; 5(9):1025-40. PubMed ID: 23641694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
    LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
    Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
    Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG.
    Shao S; Tsai MH; Lu J; Yu T; Jin J; Xiao D; Jiang H; Han M; Wang M; Wang J
    Bioorg Med Chem Lett; 2018 May; 28(8):1363-1370. PubMed ID: 29559276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
    Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
    J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
    Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
    J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.